Form 4: Xencor CEO Bassil Dahiyat Executes Stock Transactions Under 10b5-1 Plan

Xencor's CEO, Bassil Dahiyat, executed multiple stock transactions, including option exercises and sales, under a pre-arranged 10b5-1 trading plan.

Summary

• Xencor CEO Bassil Dahiyat exercised stock options and sold shares of common stock on November 21 and 22, 2024.
• The transactions were executed under a pre-arranged 10b5-1 trading plan adopted on June 14, 2024.
• On November 21, 2024, 49,278 shares were acquired through option exercise at $15.69 per share and then sold at a weighted average price of $24.0749 per share.
• On November 22, 2024, 13,548 shares were acquired through option exercise at $15.69 per share.
• Following these transactions, Dahiyat directly owns 366,163 shares of common stock and 8,808 stock options.

Sentiment

Score: 6

Explanation: The document reflects routine insider transactions under a pre-arranged plan, which is neither particularly positive nor negative. The sale of shares could be seen as slightly negative, but the overall sentiment is neutral.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for corporate insiders to avoid accusations of insider trading.
• The CEO exercised options at $15.69 and sold shares at a higher weighted average price of $24.0749, indicating a profitable transaction.

Negatives

• The sale of 49,278 shares by the CEO could be interpreted negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react to the CEO's stock sales, potentially causing short-term price fluctuations.
• Reliance on a 10b5-1 plan does not eliminate all risks associated with insider trading perceptions.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry where stock options are a significant part of executive compensation. The use of a 10b5-1 plan is a standard practice to manage insider trading risks.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives in publicly traded companies, including those in the biotechnology sector such as Amgen, Regeneron, and Gilead Sciences.
• Stock option grants and exercises are a typical component of executive compensation packages in the biotech industry, similar to practices at companies like Biogen and Vertex Pharmaceuticals.
• The reported transaction prices are within the expected range for stock transactions of this nature, given the current market conditions and Xencor's stock performance.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, potentially causing short-term price fluctuations.
• The transactions do not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Xencor, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, Bassil Dahiyat, Stock Sale, Executive Compensation